Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Venous gangrene associated with COVID-19: Successful limb preservation strategies with optimal wound management

Dominic N. Facciponte a, *, Palma Shaw b

a College of Medicine, SUNY Upstate Medical University, United States
b Department of Surgery, Division of Vascular and Endovascular Services, SUNY Upstate Medical University, United States

ARTICLE INFO

Keywords:
COVID-19
Amputation
Deep venous thrombosis
Venous gangrene
Wound care
Limb salvage

ABSTRACT

During the COVID-19 pandemic, high rates of arterial and venous thromboembolic (VTE) events were noted in association with increased rates of major amputation. VTE appears to be a significant source of morbidity and mortality for this patient population and numerous methods have been described to achieve limb salvage. Nevertheless, best management remains unclear. We describe the case of a 60-year-old male with severe venous gangrene secondary to a non-occlusive mid-femoral and occlusive infraoplateal deep venous thromboses associated with COVID-19 infection who ultimately underwent meticulous local wound care and transmetatarsal amputation, which allowed for maximal preservation of foot function and limb salvage.

Introduction

Venous thromboembolism (VTE) events such as deep venous thrombosis (DVT) and pulmonary embolism (PE) are well-documented occurrences associated with severe acute respiratory syndrome coronavirus-2 infection, otherwise known as COVID-19. Current evidence suggests that these events are associated with hypercoagulable and inflammatory states induced by viral infection and endothelial dysfunction. Current recommendations recommend VTE prophylaxis for inpatients with confirmed COVID-19 infection with severe infection, comorbidities, and immobilization. Close monitoring of this patient population for DVT/PE should prompt immediate intervention and transition to therapeutic anticoagulation.

Furthermore, pedal gangrene associated with VTE in the context of COVID-19 infection has been reported in some case reports. Currently, methods such as anticoagulation alone, mechanical thrombectomy, catheter-directed thrombolysis, prone positioning with venovenous extracorporeal membrane oxygenation, and amputation have been trialed with varying levels of success. In other similar reports, COVID-positive patients with concomitant VTE and arterial thromboembolism (ATE) ultimately required more proximal amputation in the acute setting. Here we present the case of a 60-year-old male who presented with significant venous gangrene of the left lower extremity secondary to COVID-19 infection. To the best of our knowledge, we report the first case in which the primary method of limb salvage was via a combination of anticoagulation, meticulous local wound care allowing for ischemic demarcation, and transmetatarsal amputation (TMA).

Case report

The patient is a 60-year-old male with a past medical history of hypertension who presented to the emergency department at an outside hospital after being found down at home for approximately one to two weeks secondary to a fall (according to a family member). At the time his chief complaint was of left lower extremity rest pain. On physical exam, the patient was edematous to the mid-thigh on the left, compartments were soft, and there was intact foot dorsiflexion and planter flexion with preserved sensorium in the left first web space. The foot appeared cyanotic and ischemic, particularly in toes one through five with purple discoloration in the forefoot through just above the ankle (Fig. 1).

As part of the initial workup, the patient underwent arterial duplex ultrasonography (US) which revealed no arterial stenosis or occlusion with accompanying triphasic waveforms in the bilateral lower extremities. Ankle-brachial indices and additional lower extremity imaging were not performed due to the normal arterial duplex findings. Lower extremity examination on the right was within normal limits. Lower extremity venous duplex US revealed a non-occlusive left mid-femoral DVT as well as occlusive thromboses of the left anterior tibial, peroneal, and posterior tibial veins (Fig. 2).

* Presented at the 48th Annual Meeting of the New England Society for Vascular Surgery; Professor’s Rounds Series; October 16, 2021
* Corresponding author.
E-mail address: facciponte.dominic@gmail.com (D.N. Facciponte).

https://doi.org/10.1016/j.avsurg.2022.100095
Received 7 March 2022; Received in revised form 22 April 2022; Accepted 21 May 2022
2772-6878/© 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Additionally, the patient was in respiratory failure, requiring high flow oxygen but ultimately avoided intubation. In the emergency department he received computed-tomography (CT) scan of the thorax that revealed extensive patchy bilateral airspace disease and multiple small, subsegmental PE and was found to be COVID-19 positive (Fig. 3). Secondary causes of DVT were not investigated in this patient. Initial clinical exam, history and laboratory findings were unsuggestive of occult malignancy or hematologic/thrombophilic conditions. Admitting diagnoses were left lower extremity DVT, acute kidney injury (AKI), rhabdomyolysis, and bilateral subsegmental PEs with acute-on-chronic hypoxic respiratory failure secondary to COVID-19 pneumonia. In hospital, the patient required Remdesivir and Decadron treatment for respiratory failure.

Vascular surgery at our institution was consulted and given the acuity of his respiratory status, no acute vascular intervention was performed. Anticoagulation was initially managed with intravenous unfractionated heparin (IVH) drip transitioned to direct oral anticoagulation (DOAC) treatment with Eliquis. IVH was selected due to the presenting diagnosis of acute kidney injury secondary to rhabdomyolysis. On admission, creatinine was 1.47 and the kidney injury resolved during the hospital stay prior to discharge. Given the resolution of the kidney injury before starting DOAC treatment and the lack of any preceding chronic renal disease, renal dosing adjustments to the Eliquis regimen were not indicated and he was started on 5 mg twice per day.

In lieu of surgical intervention, local wound care management and observation allowed demarcation to define level of ischemia while he completed anti-coagulation treatment. The patient’s forefoot and left lower extremity gangrene initially was widespread however by mid-admission had demarcated to the transmetatarsal level of the left foot (Fig. 4a). In-hospital, local wound care was performed using Xeroflow, gauze and kerlix wrapping. Prior to discharge (on hospital day 25) the majority of venous gangrene demarcated at the level of the patient’s toes (one through five), including both the dorsum and plantar aspects of the foot (Fig. 4b).

Following the duration of anticoagulation, the patient has been followed regularly in the outpatient clinic and with venous duplex US at three months. Findings of the repeat duplex US revealed a stable, non-occlusive, and chronic mid-femoral DVT, while the infra-popliteal DVTs...
remained chronically stable and occlusive. Local wound care was continued and transitioned to Aquacel Ag. The wound ultimately demarcated to the majority of toe one, and the distal aspects of toes two through five with involvement of the plantar aspect of the foot (Fig. 4c). Preoperatively, there was no clinical evidence of arterial disease. Given the extensive ischemic damage to the toes, a toe-brachial index (TBI) was not attainable, however repeated doppler examination demonstrated biphasic blood flow suggestive of good arterial supply. Thus, the patient was presumed to have sufficient arterial supply to heal the wound after surgical intervention. Due to the ischemia observed in the plantar flap, we elected for left TMA with primary closure (Fig. 4d). On follow-up in clinic, the patient’s TMA site has remained well-healed, and he is ambulating using his left foot without any difficulty (Fig. 4e).

Discussion

Since the start of the pandemic, there have been numerous case reports and clinical studies documenting the impact of COVID-19 infection on the cardiovascular system such as ATE and VTE, limb ischemia, myocarditis, and stroke/transient ischemic attack. Moreover, a study by

Fig. 3. CTA Thorax demonstrating extensive patchy bilateral airspace disease consistent with COVID-19 pneumonia as well as multiple small, subsegmental PEs (yellow arrows).

Fig. 4. Appearance of the patient’s lower extremity wound at various stages of care reveals demarcation of ischemia and ultimate appearance after TMA. (a) Mid-admission the wound demarcated to the transmetatarsal level. (b) By hospital day 25 with careful wound care, there was vast improvement with disease primarily involving toes one through five. (c) Appearance at three months follow-up after transition to wound care with Aquacel Ag reveals the wound included the plantar aspect of the foot. (d) Immediate and one month (e) post-operative outcomes following TMA with excellent wound healing.
Schievens et al. reports on the observed increased incidence of ampu-
tations both related to COVID-19 infection and other primary vascular
disease, such as peripheral arterial disease.15

Recent literature suggests that COVID-19-associated vascular path-
ology is largely due to a hypercoagulable-induced state along with sys-
temic inflammation.2,3,4 Namely, it has been proposed that this is due to
diseases involving inflammatory cytokines and endothelial cell dys-
function/ viral infection of the endothelium ultimately leading to in-
flammatory thrombosis and coagulopathy.2,3,4 A systematic review and
meta-analysis by Knutsor and Laukkane concluded that hospitalized
patients with COVID-19 (especially for “severe” disease) have a high in-
cidence of thromboembolic events and complications.2 Moreover, the
authors suggest that VTE occurs at a higher incidence than arterial
thromboembolism.6

In accordance with published guidelines published, the patient was
treated for VTE with anticoagulation according to the following: For
acutely ill patients hospitalized with COVID-19 and associated proxi-
mal DVT or PE, initial treatment is parenteral anticoagulation with low-
weight molecular heparin (LMWH) or IFN,7,16,17 When transitioned to
outpatient care, these guidelines recommend using DOAs for such pa-
tients.7,16,17 Furthermore, pedal gangrene secondary to COVID-19 in-
fection has been described in numerous case reports and appears to be
related to VTE. Management with VTE prophylaxis versus therapeu-
tic anticoagulation, local wound care, and consideration of amputation
based on severity of illness and functional status are all methods that
have been utilized.8,12

The abovementioned literature allows us to observe a few trends.
First and foremost, VTE associated with COVID-19 is an uncharted ter-
ritory with currently evolving literature. Second, standard management
techniques are not sufficient. For instance, at our institution we noted
that during the peak of the pandemic, COVID-positive patients presented
with arterial lower extremity events and VTE at not only higher rates
than expected, but also were often resistant to standard measures. These
measures have included not only anti-coagulation, but also mechanical
thrombectomy and catheter-directed thrombolysis.

Finally, it is critical to discuss the methodology in caring for this
patient’s ischemic wound. In this case, our method of medical manage-
ment and anticoagulation first combined with meticulous wound care
and a “watch and wait” approach allowed for limb salvage and a good
functional outcome. This abides by the principle that foot length preser-
vation preserves foot function.18,20 In a similar case report by Chun et
al., we learn of a patient who presented with phlegmasia cereu-
dolens despite being on chronic warfarin therapy who ultimately under-
went mechanical thrombectomy and below-knee amputation (BKA).9
It should be noted that the authors nicely point out that their strategy
of mechanical thrombectomy first followed by BKA allowed for preser-
vation of limb length in this patient who may have otherwise required an
above-knee amputation (AKA).9 Additionally, other reports have docu-
cmented cases in which both ATE and VTE have occurred simultane-
ously, necessitating more proximal amputation.13,14 Future studies may con-
side investigating the severity of lower extremity ischemia and level of
amputation with ATE versus VTE or both in combination.

In our case we see that observation and meticulous local wound care
allowed for ischemic demarcation to the transmetatarsal level, primarily
involving the digits necessitating TMA only. Thus, our unique approach
towards wound care and limb salvage for lower extremity venous gangrene
secondary to COVID-19 VTE allowed for the avoidance of more proxi-
mal lower extremity amputation (e.g., BKA/ AKA). Our patient has ex-
perienced excellent wound healing with return to ambulation and daily
activities of living.

Conclusion

This case adds to the literature involving proper management of VTE
and venous gangrene in COVID-19 patients. Our unique approach, util-
izing a combination of adherence to anticoagulation guidelines, metic-
ulous wound care, and limb salvage techniques allowed for preserved
ambulatory function in a patient who may otherwise have undergone
more proximal amputation in the acute setting.

Consent

The patient provided verbal consent to the publication of the case
details and clinical images.

Declaration of Competing Interest

The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influ-
ence the work reported in this paper. The authors declare the following
financial interests/personal relationships which may be considered as
potential competing interests:

Supplementary materials

Supplementary material associated with this article can be found, in
the online version, at doi:10.1016/j.avsz.2022.100095.

References

1. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or throm-
boembolic disease: implications for prevention, antithrombotic therapy, and follow-
up. JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950–2973
20200615/. doi:10.1016/j.jacc.2020.04.031.
3. Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagula-
ble state in COVID-19: incidence, pathophysiology, and management. Thromb
Res. 2020;194(1):101–115. doi:10.1016/j.thromres.2020.06.029.
4. Oli AT, Barnes GD, Napolitano LM, Henke PK, Wakefield TW. Venous thrombosis
epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute
respiratory syndrome coronavirus 2 infection. J Vasc Surg Venous Lymphat
Disord. 2021;9(1):23–35. doi:10.1016/j.jvsv.2020.08.030.
5. Lee LH, Gallus A, Jindal R, Wang C, Wu CC. Incidence of venous thromboembolism
in Asian populations: a systematic review. Thromb Haemost. 2017;117(12):2243–2260
Dec. doi:10.1160/TH17-02-0134.
6. Cai S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients
with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–1424
Jun. doi:10.1111/j.1477-7517.2020.12730.
7. Kunutsor SK, Laukkane JA. Incidence of venous and arterial thromboembolic
complications in COVID-19: a systematic review and meta-analysis. Thromb
Res. 2020;196:27–30. doi:10.1016/j.thromres.2020.08.022.
8. Moores I, Tritschler T, Bronnahan S, et al. Prevention, diagnosis, and treatment of
VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel
report. Chest. 2020;158(3):1143–1163. doi:10.1016/j.chest.2020.05.599.
9. Siegel A, Al Rubaiai A, Adelsheimer A, Haight J, Gawlik S, Oropallo A. Pedal gan-
grene in a patient with COVID-19 treated with prone positioning and extracor-
oral membrane oxygenation. J Vasc Surg Cases Innov Tech. 2021;7(2):357–360.
doi:10.1016/j.jvscit.2021.02.013.
10. Chun TT, Jimenez JC, Pantoja JL, Moriarty JM, Freeman S. Phlegmasia cereu-
dolens associated with acute coronavirus disease 2019 pneumonia despite suprather-
apeutic anticoagulation. J Vasc Surg Cases Innov Tech. 2020;6(4):653–656.
doi:10.1016/j.jvscit.2020.09.002.
11. Bamboje A, Hong J, Mushiyev S, Pekler G. A 61-year-old man with SARS-CoV-2
infection and venous thrombosis presenting with painful swelling and gangrene of
the lower limb consistent with phlegmasia cerulea dolens. Am J Case Rep. 2020;
21:e232642.e1–e232642.e6. doi:10.1177/2151358520942342.
12. Visveswaran GK, Morpia K, Narang S, et al. Severe acute respiratory syn-
drome coronavirus 2 infection and thrombosis: phlegmasia cerulea dolens pre-
senting with venous gangrene in a child. J Pediatr. 2020;236:281–284.e1.
doi:10.1016/j.jpeds.2020.07.022.
13. Lee KA, McBride RS, Narlawar R, Myers R, Antoniou GA. COVID toces: concurrent
lower limb arterial and venous thromboembolism in a patient with COVID-19 pneu-
monitis presenting with foot ischemia. Vasc Endovasc Surg. 2022;56(2):201–207.
doi:10.1177/15385744211045600.
14. Del Castillo-García S, Minguino-Carazo C, Echarte JC, et al. A case report of arterial
and venous thromboembolism in a patient with severe COVID-19 pneumonia. Eur
Heart J Case Rep. 2020;4(6):1–6. doi:10.1093.echjr/zyaa030.
15. Madani MH, Leung ANC, Becker HC, Chan PP, Fleischmann D. Aorto-iliac/right
leg arterial thrombosis necessitating limb amputation, pulmonary arterial, intracar-
diac, and ilio-caval venous thrombosis in a 40-year-old with COVID-19. Clin Imag.
2021;75:1–4. doi:10.1016/j.clinimag.2020.12.036.
16. Schievens PME, Buijs M, Boonman-de Winter L, et al. Impact of the COVID-19 lock-
down strategy on vascular surgery practice: more major amputations than usual. Ann
Vasc Surg. 2020;69:74–79. doi:10.1016/j.avsg.2020.07.025.
16. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. *N Engl J Med*. 2021;385(9):777–789. doi:10.1056/NEJMoa2103417.

17. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. *N Engl J Med*. 2021;385(9):790–802. doi:10.1056/NEJMoa2105911.

18. Suckow BD, Goodney PP, Cambria RA, et al. Predicting functional status following amputation after lower extremity bypass. *Ann Vasc Surg*. Jan 2012;26(1):67–78. doi:10.1016/j.avsg.2011.07.014.

19. Dillon M.P., Barker TM. Preservation of residual foot length in partial foot amputation: a biomechanical analysis. *Foot Ankle Int*. Feb 2006;27(2):110-6. doi:10.1177/107110070602700207.

20. Vogel TR, Petroski GF, Kruse RL. Impact of amputation level and comorbidities on functional status of nursing home residents after lower extremity amputation. *J Vasc Surg*. 2014;59(5):1323–1330.e1. doi:10.1016/j.jvs.2013.11.076.